Clinical trials: Depressions, Refractory
Major Depressive Disorder, Suicide
i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial
Approximately four thousand Canadians die by suicide every year, and suicide is the second leading cause of death in youth and young adults (15-34 years).
- Conditions
- Major Depressive Disorder, Suicide, Treatment Resistant Depression
- Trial name
- Ket-CBT (NCT06480500)
- Testing
- Ketamine hydrochloride, i-CBT (Internet-based Cognitive Behavioural Therapy), Midazolam Hydrochloride
- Where
- Canada
- Volunteers
- 76 people
- Sponsor
- University Health Network, Toronto
Unipolar Depression
Ketamine Trial for the Treatment of Depression
This study is a Randomized Controlled Trial, investigating the safety and efficacy of administration of ketamine as a potential treatment for depression.
- Trial name
- NCT02401139
- Testing
- Ketamine
- Where
- 2 sites in Australia
- Volunteers
- 10 people
- Sponsor
- The University of New South Wales
Multiple Sclerosis, Major Depressive Disorder
Acceptability and Feasibility of Transcranial Magnetic Stimulation (TMS) for Depression in Multiple Sclerosis
The goal of this single-arm, observational pilot study is to learn about the safety, feasibility, preliminary efficacy of TMS for the treatment of depression in people with MS.
- Conditions
- Multiple Sclerosis, Major Depressive Disorder, Treatment Resistant Depression
- Trial name
- NCT06329414
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Utah
Depressive Disorder, Treatment-Resistant
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy and safety of switching elderly participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to either…
- Trial name
- TRANSFORM-3 (NCT02422186)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant)
- Where
- 69 sites in United States, Belgium and 10 more
- Volunteers
- 139 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder, Treatment Resistant Depression
The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Over 28 million people suffer from current depressive disorder in the European Union. Major depressive disorder (MDD) is one of the most common psychiatric illnesses.
- Trial name
- INTENSIFY MDD (NCT05973851)
- Testing
- Esketamine Nasal Product, Ketamine Hydrochloride, Esketamine hydrochloride
- Where
- 12 sites in Austria, Germany and 4 more
- Volunteers
- 418 people
- Sponsor
- Dr. Inge Winter
Treatment Resistant Depressive Disorder
Ketamine for Treatment Resistant Late-Life Depression
The purpose of this study is to examine the effectiveness of a single infusion of ketamine (KET), to determine which dose is optimal 7 days after infusion using Bayesian Adaptive Randomization, and to learn about how ketamine…
- Trial name
- NCT02556606
- Testing
- Ketamine, Midazolam
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- VA Office of Research and Development
Major Depression
Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
The purpose of this multi-site randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of depression in U.S.
- Trial name
- PIVOT (NCT07226232)
- Testing
- Psilocybin
- Where
- 5 sites in United States
- Volunteers
- 240 people
- Sponsor
- VA Office of Research and Development
Treatment Resistant Depression
Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine
This study aims to assess the efficacy and safety of intranasal esketamine as maintenance antidepressant therapy in patients who have demonstrated clinical improvement with off-label intravenous racemic ketamine for…
- Trial name
- NCT04856124
- Testing
- Intranasal esketamine
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Psych Atlanta
Depressive Disorder
Evaluating the Efficacy of Magnetic Seizure Therapy in Treatment Resistant Depression.
Electroconvulsive therapy (ECT) has unparalleled efficacy in treating severe depression that is resistant to common modalities of treatment, such as antidepressant medication.
- Trial name
- NCT01748708
- Testing
- Magnetic seizure therapy, Electroconvulsive therapy
- Where
- Canada
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder, Major Depressive Episode
Glabellar Botulinum Toxin Injections for the Treatment of Geriatric Depression
The effectiveness of glabellar injection of botulinum toxin type A (BTA) in treating depression has not yet been investigated in elderly patients.
- Conditions
- Major Depressive Disorder, Major Depressive Episode, Treatment Resistant Depression
- Trial name
- BOTDEP (NCT03833063)
- Testing
- botulinum toxin A
- Sponsor
- Helse Stavanger HF
Treatment Resistant Depression, Major Depressive Disorder
Sustained Mood Improvement With Laughing Gas Exposure: A Randomized Controlled Pilot Trial
The purpose of the study is to investigate a short-term treatment option for major depressive disorders by administering nitrous oxide gas.
- Trial name
- SMILE (NCT04957368)
- Testing
- Nitrous Oxide 99 %, Oxygen + Midazolam
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Unity Health Toronto
Treatment Resistant Depression, Major Depressive Episode
University of Iowa Interventional Psychiatry Service Patient Registry
The purpose of this study is to examine the effects of interventional/procedural therapies for treatment-resistant depression (TRD) and Obsessive-Compulsive Disorder (OCD).
- Conditions
- Treatment Resistant Depression, Major Depressive Episode, Major Depression, Major Depressive Disorder
- Trial name
- NCT04480918
- Testing
- Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Ketamine
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Mark Niciu
Depression
SMTr-METAB : FDG-PET Assessment of Cerebral Metabolism in Resistant Depression Treated With rTMS
Biological markers of depressive states have been studied, but their usefulness to predict the therapeutic response is unknown. This issue is major in all depressive states which have not remitted after several lines of…
- Trial name
- SMTr-METAB (NCT02754375)
- Testing
- rTMS
- Where
- 2 sites in France, Monaco
- Volunteers
- 22 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Treatment Resistant Depression
Ketamine Frequency Treatment for Major Depressive Disorder
Depression is a wide spread illness. Depression contributes most significantly to national health care costs. While the number and types of treatments used for depression have expanded over the years, even with an increased range…
- Trial name
- NCT00646087
- Testing
- Ketamine, Ketamine/Saline
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Essentia Health
Major Depressive Disorder, Treatment-Resistant Depression
Antidepressant Effects of TS-161 in Treatment-Resistant Depression
Background: Major depressive disorder (MDD) is a common, chronic mental illness. It can take weeks to months for antidepressants to work. Researchers want to test a new drug that might act more rapidly.
- Conditions
- Major Depressive Disorder, Treatment-Resistant Depression, Depression
- Trial name
- NCT04821271
- Testing
- TS-161
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder, Treatment Resistant Depression
Identifying Local Field Potential Biomarkers for Treatment-Resistant Major Depression With Deep Brain Stimulation
Major depressive disorder (MDD) is a complex and severe mental illness, characterized by multiple symptoms, and is a leading cause of non-fatal health loss.
- Trial name
- NCT06542094
- Testing
- Deep Brain stimulation
- Where
- China
- Volunteers
- 12 people
- Sponsor
- West China Hospital
Depressive Disorder, Depressive Disorder, Major
Synaptic Imaging and Network Activity in Treatment Resistant Depression
The main aim of this research is to explore the effects that ketamine has on the functional connectivity of the brain in participants with treatment resistant depression (TRD).
- Conditions
- Depressive Disorder, Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant, Bipolar Disorder
- Trial name
- SIGNATURE (NCT05870501)
- Testing
- Ketamine, Midazolam
- Where
- United Kingdom
- Volunteers
- 56 people
- Sponsor
- King's College London
Major Depressive Disorder
Behavioral and Electrophysiological Effects of Ketamine in Treatment-Resistant Depression
The overarching goal of the present study is to evaluate the effect of a subanesthetic dose of ketamine 24-hour post-injection on resting state functional connectivity, cognitive control, and reward learning.
- Trial name
- NCT04239963
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Suicidal Ideation, Major Depressive Disorder
N2O for Acute Suicidality and Depression in the ED
Investigators are conducting this double-blind, randomized control trial (RCT), to compare inhaled N2O+ treatment as usual (TAU) versus inhaled placebo+TAU; demonstrating the feasibility and tolerability of the intervention in an…
- Conditions
- Suicidal Ideation, Major Depressive Disorder, Treatment Resistant Depression
- Trial name
- NCT05710887
- Testing
- Nitrous oxide gas for inhalation
- Where
- United States
- Sponsor
- University of Chicago
Treatment Resistant Depression, Epilepsy
Mapping and Modulating the Spatiotemporal Dynamics of Socio-Affective Processing
The overall goal of this study is to map the spatiotemporal dynamics of social affective processing and to examine selective modulation of these dynamics in humans undergoing invasive intracranial monitoring for…
- Trial name
- NCT05418894
- Testing
- Device: Directional Deep Brain Stimulation
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine